Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

NCT06715189 | Not Yet Recruiting

• 1 other identifier: Soh-Med-24-11--5MD
• Study Type: observational
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Conditions

Hepatic Fibrosis

Outcome Measures

Primary Outcomes (1)

• degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus

  adiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM

  1 year

Study Arms (2)

MASLD patients with hepatic fibrosis

MASLD with hepatic fibrosis with type 2 diabetes mellitus

Diagnostic Test: serum Adiponectine and Resistin; Diagnostic Test: fibroscan

MASLD without hepatic fibrosis

MASLD with out hepatic fibrosis with type 2 diabetes mellutis

Diagnostic Test: serum Adiponectine and Resistin; Diagnostic Test: fibroscan

Interventions

serum Adiponectine and Resistin DIAGNOSTIC_TEST

corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

MASLD patients with hepatic fibrosis; MASLD without hepatic fibrosis

fibroscan DIAGNOSTIC_TEST

hepatic fibrosis detection in type 2 diabetes mellutis

MASLD patients with hepatic fibrosis; MASLD without hepatic fibrosis

Eligibility Criteria

• Age: 30 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

MASLD patients with hepatic fibrosis groupA,MASLD patients without hepatic fibrosis

You may qualify if:

• patients of both sex who have type2 Diabetes Mellitus for less than five years

Sponsors & Collaborators

• Sohag University: lead

Related Publications (4)

• Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.

  PMID: 37700494 BACKGROUND

• Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. J Hepatol. 2024 Feb;80(2):178-180. doi: 10.1016/j.jhep.2023.10.011. Epub 2023 Nov 30. No abstract available.

  PMID: 38278621 BACKGROUND

• Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.

  PMID: 36517002 BACKGROUND

• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.

  PMID: 28802062 BACKGROUND

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

ELZAHRAA K Mohammed, spcialist

CONTACT

01064954825; elzahraaadbelrehem@sohag.edu.eg

usama M Abdelaal, professor

CONTACT

01065962094

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Teaching assistant fellow At sohag teaching hospital

Study Record Dates

• First Submitted: November 28, 2024
• First Posted: December 4, 2024
• Study Start: December 1, 2024
• Primary Completion: December 1, 2025
• Study Completion: December 30, 2025
• Last Updated: December 4, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share